Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

NCT07347405 | Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: 00005573
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute.

Conditions

Obsessive-Compulsive Disorder

Outcome Measures

Primary Outcomes (3)

• Yale Brown Obsessive Compulsive Scale

  Clinician rating scale to determine severity of OCD symptoms. Scores vary from 0 to 40. Higher scores represent greater severity of OCD symptoms.

  Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase).

• Adverse Event (AE) Tracking log

  The Adverse Event tracking log will collect information on adverse health events reported throughout the research study.

  Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase).

• Visual Analogue Scale (VAS)

  Self-reported measure of intensity or frequency of pain or other various symptoms

  Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase). Scale 0 (no symptoms at all) to 100 (maximum symptom severity)

Secondary Outcomes (3)

• World Health Organization's quality of life assessment (WHOQOL-BREF)

  Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase).

• Short form health survey (SF-36)

  Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase). Functionality scales are transformed to range from 0 to 100 with 0 being maximal disability and 100 being no disability.

• Columbia-Suicide Severity Rating Scale (C-SSRS)

  Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase). Individuals with positive ideation or behavior scores can be categorized into low, moderate or high risk of suicide.

Study Arms (3)

Low dose 10 mg

EXPERIMENTAL

Whole dried psilocybin mushroom containing 10 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.

Drug: Psilocybin 10 mg

Middle dose 20 mg

EXPERIMENTAL

Whole dried psilocybin mushroom containing 20 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.

Drug: Psilocybin 20 mg

High dose 30 mg

EXPERIMENTAL

Whole dried psilocybin mushroom containing 30 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.

Drug: Psilocybin 30 mg

Interventions

Psilocybin 10 mg DRUG

Oral administration of whole dried psilocybin mushrooms contained in a chocolate matrix.

Low dose 10 mg

Psilocybin 20 mg DRUG

Oral administration of whole dried psilocybin mushrooms contained in a chocolate matrix.

Middle dose 20 mg

Psilocybin 30 mg DRUG

Oral administration of whole dried psilocybin mushrooms contained in a chocolate matrix.

High dose 30 mg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18 years old, and older
• Have OCD (DSM-5) based on diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID).
• At least moderate severity: Yale-Brown Obsessive Compulsive Scale (YBOCS) score ≥16.
• Failed at least one adequate trial of guideline concordant treatment.
• Considered safe for independent living
• Subjects must discontinue use of any of the following prescription or over the counter (OTC) products or nutritional supplements at least two weeks prior to initiating double-blind treatment:
• Monoamine oxidase (MAOI), UGT1A10, and UGT1A9 inhibitors
• Other active OCD treatments (cognitive behavioral therapy \[CBT\] or other psychotherapy; electrical or magnetic device treatments; pharmacological treatments such as antidepressant medications (e.g., SSRIs, SNRIs, MAOIs, TCAs, 5HT2 blockers, NERIs, etc.), lithium, antipsychotic drugs, 5-HT2 antagonists such as pimavanserin, and glutamatergic acting medications)
• \* Note that fluoxetine must be discontinued at least 6 weeks prior to initiating double-blind treatment.
• HT2 agonists (e.g., efavirenz, lorcaserin), which may alter the response to psilocybin
• Serotonin-acting dietary supplements (e.g., 5-hydroxy-tryptophan, St. John's wort) due to potential for interaction with psilocybin and increased safety risks

You may not qualify if:

• Concurrent active substance use disorder, or a personal history of psychosis.
• History of psychosis among first degree relatives as determined by the Family Interview for Genetic Studies (FIGS)32
• Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion. Examples include: 1) Cardiovascular conditions: lifetime history of stroke, lifetime myocardial infarction, uncontrolled hypertension (resting blood pressure \>140/90 mmHg), tachycardia (resting heart rate \>100 beats per minute), elongated QT interval corrected by Fridericia's formula (QTcF; interval \>450 msec), participants with existing valvular heart disease, or clinically significant arrhythmia (\<1 year prior to signing the ICF); 2) Metabolic conditions: subjects with diabetes should have a stable diabetes treatment regimen and no history of diabetic ketoacidosis, hyperglycemic coma, or no hypoglycemic episodes with glucose below 54 mg/dL in the 3 months prior to baseline, and fasting glucose \>70 mg/dL at baseline; 3) Severe renal impairment: eGFR \<45 mL/min/1.73 m²); and Liver failure: Child-Pugh Classes B and C.
• Unstable Chronic Obstructive Pulmonary Disease (COPD) or severe sleep apnea
• Clinically significant renal or hepatic impairment, per clinical judgment of a study physician
• EKG QTc ≥ 450 msec
• Psychiatric comorbidity that may represent an acute risk to their own or other's safety, including history of bipolar disorder (I or II) in the participant or first degree relative, as well as any family history of psychosis.
• Subjects cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving.
• Participants who are pregnant, breastfeeding, planning a pregnancy, or planning to donate sperm within three months post-last study drug administration.
• Participants of childbearing potential or participants with partners of childbearing potential who engage in intercourse which could result in pregnancy are unwilling/unable to practice medically acceptable highly effective birth control (double barrier, oral and injectable pharmacological contraceptives, or surgical such as vasectomy or bilateral tubal occlusion) during the study and up to three months after the last study drug administration.
• Suicide attempt within the 12 months prior to enrollment
• Any condition for which MRI is contraindicated, at the discretion of a study investigator or the MRI technician, including: Pacemakers and defibrillators; artificial heart valves which are not MRI safe; any metal in head, spinal cord, eyes or chest; any electrical devices such as cochlear implants, nerve stimulators, deep brain stimulators, gastric pacemaker, or insulin or pain pumps; aneurysm clips; ferrous (i.e. non titanium alloy) implants in any part of the body.
• Use within the week prior to screening of drugs of abuse as listed in the current US DOJ DEA Drugs of Abuse Resource Guide, including:
• Cannabinoids (marijuana, synthetic cannabinoids)
• Simulants (amphetamine, cocaine, methamphetamine, methylphenidate, modafinil)

Sponsors & Collaborators

• Francisco A Moreno: lead
• Arizona Biomedical Research Commission (ABRC): collaborator

Study Sites (1)

The Clinical and Translational Sciences Research Center

Tucson, Arizona, 85724, United States

RECRUITING

MeSH Terms

Conditions

Obsessive-Compulsive Disorder

Interventions

Psilocybin

Condition Hierarchy (Ancestors)

Anxiety Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Indole Alkaloids; Alkaloids; Heterocyclic Compounds; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Tryptamines; Indolizidines; Indolizines

Study Officials

• Francisco Moreno, MD

  University of Arizona

  PRINCIPAL INVESTIGATOR

Central Study Contacts

The clinical and translational research center

CONTACT

(520) 626-8000; OCD@psychiatry.arizona.edu

Study Coordinator

CONTACT

(520) 626-4804

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: MD, Professor of Psychiatry

Study Record Dates

• First Submitted: December 22, 2025
• First Posted: January 16, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): January 1, 2029
• Last Updated: February 18, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)